Company intelligence / Profile preview

SD BIOSENSOR

Suwon, Gyeonggi-do/Suwon-si/Yeongtong-gu, South Koreasdbiosensor.com ↗

Ownership: Private
Development stage: Other

Overview

SD BIOSENSOR has commercialized a broad portfolio of in-vitro diagnostic products including rapid tests for infectious diseases such as COVID‑19 and tuberculosis, blood glucose meters for diabetes management, ELISA kits for mass screening, and point-of-care molecular diagnostics systems. The company’s platforms are widely used globally with proven high sensitivity and specificity in clinical settings

Therapeutic areas: EndocrinologyInfectious DiseasesOther
Modalities: DeviceDiagnostic reagent
Industry: Molecular Diagnostics

Partnerships

Bill & Melinda Gates Foundation investmentWHO/MPP technology transfer license to expand access to essential diagnostics in LMICs

Beyond the preview

Go deeper on SD BIOSENSOR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SD BIOSENSOR.

Explore the full profile